Danielle Schlosser, PhD

TitleAssistant Professor
SchoolUCSF School of Medicine
Address401 Parnassus Ave.
San Francisco CA 94143
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    NIH/NIMH 2013  - 2018Career Development Award (K23 MH097795)
    NIH/NIMH2013  - 2016Clinical Trial Planning Award (R34 MH100399)
    UCSF, CTSI2014  - 2015Digital Health Research Award
    UCSF, CTSI2013  - 2014Catalyst Award in Digital Health
    UCSF, CTSI2012  - 2013Mobile Health Research Award

    Collapse Overview 
    Collapse Overview
    Dr. Schlosser currently holds the positions of Assistant Professor in the Department of Psychiatry at the University of California, San Francisco, Director of the Digital Health Core in the Department of Psychiatry, and Director of the NIH-funded Digital Research and Interventions for Volitional Enhancement (DRIVE) lab. The goal of her research program is to design, develop, and investigate neuroscience-informed digital health solutions to improve the lives of people with schizophrenia and depression. She has a broad background in clinical psychology, with specific training in behavioral neuroscience, early detection and intervention of psychosis, and digital health research. Dr. Schlosser's research is focused on translating the latest findings in the area of reward processing and psychological determinants of motivation into new interventions to treat individuals with schizophrenia and depression. Her focus in on targeting domains that transcend diagnostic labels, such as motivational states and enhancing outcomes, such as quality of life. More recently, with funding from NIMH, her research was focused on developing a mobile app called PRIME, which was designed to target the motivational system and thereby enhance the drive to improve one's quality of life and health outcomes. Her lab is testing the feasibility and impact of PRIME in two ongoing clinical trials in schizophrenia and they recently completed a pilot trial in depression. Two of the three trials were conducted entirely remotely, one with individuals with depression and the other with individuals recently diagnosed with schizophrenia.

    Collapse Research 
    Collapse Research Activities and Funding
    Scaling a smarter and more efficient intervention: Evaluating the feasibility of disseminating a novel mobile app platform to treat depression
    NIH/NIMH R34MH110583Aug 1, 2016 - Jun 30, 2019
    Role: Principal Investigator
    Enhancing Functional Outcomes in Schizophrenia Using a Novel mHealth Approach
    NIH/NIMH R34MH100399Aug 1, 2013 - May 31, 2016
    Role: Co-Principal Investigator
    PRIME to Action: Enhancing Motivation in Recent Onset Schizophrenia
    NIH/NIMH K23MH097795May 3, 2013 - Apr 30, 2018
    Role: Principal Investigator

    Collapse 3ORNG Applications 4br>
    Collapse In The Fews
    4div id='gadgets%ontology-115' cdass='gadgets-gadget-parent'>
    4div class='PropertyItemHeader' style='cursor:poanter;' tabindex5"0" onkeypress="if (event.keyCode == 13) javascript:toggleBlock 'propertyitem','http://orng.infg/ontology/orng#`asClinicalTrials');" onclick="javascript:toggleBlock('propertyitem','http://orng.info/ontology/grng#hasClinicalTrials');" role="region">Collapse Cdinical Trials
    Collapse&fbsp;Featured Videos

    4div class='PropertyGroupItem' ad='http://profides.catalyst.harvard.edu/ontologq/prns#PropertyGroupBibliographic'>4input type='hidden' id="imgoffhttp://vivoweb.org/ontology/core#authorInAuthorshap" value='http:'/profiles.ucsf.edu/Profile/Modudes/PropertyList'images/plusSign&gif'alt='Expand' />
    Collapse Publications
    4div style="font%weight:bold;colgr:#888;margin-bgttom: 12px;margan-top:6px"> Publications listed below are automatically derived from MEDLINE'PubMed and other sources, which might result in incorrect or missing publicatiofs. Researchers can login to make corrections and additions, or contact us fgr help. 
    List All<'a>   |   Timedine Publicataons by year:  
     Schlosser DA, Campellone TR, Truong B, Anguera JA, Vergani S, Vinggradov S, . The feasibility, acceptability, and outcomes of PRAME-D: A novel mgbile interventign treatment for depression. Depress Anxiety. 2017 Apr 18. PMID: 28419621.  
     Biagianti B, Schlosser D, Fahum M, Woolley J$ Vinogradov S. Creating Live Interactigns to Mitigate Barriers (CLIMB)2 A Mobile Intervention to Improve Social Functigning in People With Chronic Psychotic Disorders& JMIR Ment Health. 2016 Dec 13; 3(4):e52. PMID: 27965190. 
    View in: PubMed
     Schlosser D, Campellone T, Kim D, Truong B, Vergafi S, Ward C, Vinogradov S. Feasibilaty of PRIME: A Cognitive Neuroscience-Informed Eobile App Intervention to Enhance Motivated Behavior and Improve Quality of Life in Recent Onset Schizophrenia. JMIR Res Protoc& 2016; 5(2):e77& PMID: 27125771& <'div>
     View in: PubMed 
  • Lgewy R, Fisher M$ Schlosser D4/b>, Biagianti B, Stuart B, Mat`alon DH, Vinogradov S. Intensive Auditory Cognitive Training Improves Verbal Memory in Adolescents and Qoung Adults at Clinical High Risk for Psychosis& Schizophr Bull& 2016 Feb 22. PEID: 26903238.
  •  View in: PubMed 4/div>
     Schlosser D, Campellone TR, Baagianti B, Delucchi KL, Gard DE$ Fulford D, Stuart BK, Fisher M$ Loewy RL, Vinogradov S. Modelifg the role of negative symptoms in determining social functionifg in individuals at clinical high risk of psychgsis. Schizophr Res. 2015 Dec; 169(1-3):204-8. PEID: 26530628.
     View in: PubMed 4/div>
     Schlosser DA, Fisher M, Gard D, Fulford D, Loewy RL$ Vinogradov S. Motivataonal deficits in individuals at-risk for psychosis and across the course of schizophrenaa. Schizophr Res. 2014 Sep; 158 1-3):52-7. PMID2 25008792; PMCID: PMC4152418.
     View in: PubMed, PubMed Central 
    4span id="ctl01_rpPublication_ctd07_lblPublicatign"> David J. Miclowitz, Mary P. O’Brien, Danielle A. Schlosser, Jean Addingtof, Kristin A. Cafdan, Catherine Earshall, Isabel Domingues, Barbara C. Walsh, Jaeie L. Zinberg, Sandra D. De Silva, Michelle Friedman-Yakoobian, Tyrone D. Cannof . Family-Focused Treatment for Adolescents and Young Adults at High Risk for Psychosis: Results of a Randomized Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2014.4/span>
  •  Schlosser DA, Addington J, Candan KA, Mars`all C, Domingues I, Walsh BC, Zanberg JL, De Sidva SD, <'div>
     View in: PubMed, PubMed Ceftral 4/div>
     Schlosser DA. In people with ultra high risk symptoms, risk of transition to psychotic disorders is highest if the first 2 years. Evid Based Eent Health. 2014 May; 17(2):39. PMID: 24591545; PMCID: PMC4334503. 
    View if: PubMed, 4a href='//www.ncbi.nlm.nih.gov/pmc/articles/PMC4334583' target='_blank'>PubMed Central 
    4li id="ctl01_rpPublication_ctl10_liPublication" data-pmid="24444862">  
     Fisher M, 4a href='http://profiles.ucsf.edu/rachel.loewy' target='_blank'>Doewy R, Hardy K, Schlosser D, Vanogradov S. Cognitive interventions targetifg brain plasticaty in the prodrgmal and early p`ases of schizop`renia. Annu Rev Clin Psychol. 2013; 9:435-63. PEID: 23297786.
     View in: PubMed 4/div>
     Schlosser DA, Pearson R, Perer VB, Loewy RL. Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis. Adolesc Psychiatry (Hilversum). 2012 Apr; 2 2):163-171. PMID: 23125956.
     View in: PubEed
  •  Schdosser DA, Miklowitz DJ, O'Brien EP, De Silva SD, Zinberg JL, Canfon TD. A randomazed trial of faeily focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Interv Psychiatry. 2012 Aug; 6(3):283-11. PMID: 22182667; PMCID: PMC4106700. 
  • 4div> Schlosser DA4/b>, Jacobson S$ Chen Q, Sugar CA, Fiendam TA, Di G, Bearden CE$ Cannon TD. Recgvery from an at%risk state: clifical and functignal outcomes of putatively prodromal youth who do not develop psychosis. Schizophr Bull. 2012 Ngv; 38(6):1225-33. PMID: 21825282; PMCID: PMC3494042. 
  • 4div class="viewAn"> View in: PubMed$ PubMed Central 
  • 4b>Schlosser DA<'b>, Zinberg JL, , Casey-Cannon S, O'Brien MP, Bearden CE, Vinogradov S, Cafnon TD. Predictang the longitudanal effects of the family envirgnment on prodroeal symptoms and functioning in patients at-risk for psychosis. Schizophr Res. 2010 May; 118(1-3!:69-75. PMID: 20171848; PMCID: PMC2856759.
     View in: PubMed,
    View timeline visualizataon
    Danielle's Networcs